Navigation Links
Simuality Joins Efforts for Myanmar Relief
Date:5/9/2008

EVANSTON, Ill., May 9 /PRNewswire-USNewswire/ -- Metaverse developer Simuality LLC has joined the effort to help relieve the unspeakable human suffering in Myanmar in the wake of Cyclone Nargis. Special donation kiosks have been developed and are being placed in high-traffic locations in the virtual world of Second Life, with coordination being arranged via the Simuality welcome center on their main island (http://slurl.com/secondlife/Simuality/106/83/41).

In addition, links to the donation centers are being featured on the front pages of all of the Simuality sites, including SlippCat(TM) (http://slippcat.com), the recently unveiled metaverse advertising system, Avatrait (http://avatrait.com), the web site associated with the very popular Second Life art gallery of the same name, and the main Simuality site (http://simuality.com).

Virtual world donations are being collected in the Second Life currency of Linden Dollars. All monies collected will be donated to the International Red Cross to support their efforts to help relieve the effects of the massive devastation left by the tropical storm.

Second Life (http://secondlife.com) is the industry-leading 3-D virtual world developed by Linden Lab of San Francisco, CA.

Simuality LLC is both a full-service Metaverse developer, specializing in "sticky" builds that offer user activities and interaction for our clients, as well as an "incubator" for creating virtual world applications.


'/>"/>
SOURCE Simuality LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Booth Joins PrePak Systems for Growth, Expansion
2. Fourth Annual Games for Health Conference Joins Health and Gaming Innovators to Discuss Next-Generation Game Technologies and Health Issues
3. Senior Researcher With Extensive Healthcare Experience Joins Knowledge Networks
4. CVS Joins Retail Push for Non-Toxic Personal Care Products
5. US Chamber of Commerce Joins Protect Your Pharmacy Now! Initiative
6. Congressman Rush Joins Fight For Health Care & Financial Security
7. Medco Joins Cincinnatis Cover the Uninsured Week Effort To Deliver Lower Cost Health Care
8. Allen Kukovich, Director, Governors Southwest PA Office, Joins Call for Quality Affordable Health Insurance
9. Prominent Advocate on HIV/AIDS Issues Joins Altarum Institute
10. Gandek Joins QualityMetric to Lead International Research Effort
11. Damian DellAnno Joins Formation Capital as Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/13/2008)... Improve Your Child,s Comfort and Performance duri...wswire/ -- The Good Feet Stores, a,California base...ports and,natural sponge rubber cushions, announce...rts designed specifically for children ages 6 and ... the "SportFlex," are now,currently available at p...
(Date:5/13/2008)...ATLANTA, May 13 /PRNewswire/ -- Annually, allergie...s, causing untold suffering, sneezing and,wheezing...ication., However, putting the right air treatmen... home can create a healthier living environment an...home health specialist and,president of Sylvane.co...
(Date:5/12/2008)...YOKNEAM, Israel, May 13 /PRNewswire/ -- Lumenis In... laser, light-based and radiofrequency,devices for... announced,today the launch of a Holmium Laser Enu... that will provide training opportunities for urol...ng HoLEP. The abundance of,clinical evidence sugge...
(Date:5/12/2008)...DIANAPOLIS A study published in the May/June issue... trial providing a scientifically valid look at wh...t programs that serve low-income individuals. The ... leaders struggling to meet the needs of individua...some disease management efforts, even among relati...
Breaking Medicine News(10 mins):Health News:Good Feet Announces New Arch Support Product Line for Children Ages 6 and Older 2Health News:Simple Steps to a Healthier, Allergy-Free Home 2Health News:Simple Steps to a Healthier, Allergy-Free Home 3Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 3Health News:Chronic disease management: Does it improve health and save money? 2
... was so fazed-out when she was addicted to crystal...he used to talk to a basket . The Black Eyed Peas'...nking someone was sitting inside it, and would com...member thinking somebody was inside of it, going t...
...t of Madhya Pradesh has banned the use of vibratin... The state-run Hindustan Latex Limited (HLL) intro...months ago. Protesting its launch, Hindu hardlin...bed the condom was a sex toy going against Indian ...
...n worldwide appears to be slowing down for almost ...ice on Drugs and Crime said on Friday. "Some obvi...ghanistan, a cancer that threatens security and h...C executive director Antonio Maria Costa, ahead of...
...th sector crisis deepened Friday as pay talks brok... country's nurses, hundreds of whom are camping ou...s, which had been planned for the early hours of F... ground after each side accused the other of bad f...
Other Medicine News:Health News:Drug Addiction Slowing Down: UN Report 2Health News:Talks Break Down in Polish Nurses' Pay Protest 2
(Date:5/12/2008)... 12 /- GeoVax Labs, Inc. (O...DS vaccine development,company, announced today th...purchase agreement with Fusion Capital Fund II, LL...ompany may sell up to $10 million of its common st...month period after the Securities and,Exchange Com...
(Date:5/12/2008)...romising neurological recovery in severely-injured... treated with Cethrin, HOPKINTON, Mass., May 12 /...Inc. (Nasdaq: ALSE ) today announced 12-month int...ethrin, a proprietary recombinant,protein that is ...tor and,sensory function after spinal cord injury,...
(Date:5/12/2008)...Phase 1 Clinical Data of MDX-1100 at Digestive Dis...PRINCETON, N.J., May 12 /- ...t it has initiated the Phase 2 clinical,developmen...tibody that,targets CXCL10 (also known as IP-10), ...s (RA). MDX-1100 could potentially treat UC and RA...
(Date:5/12/2008)...in Cohort 3 Demonstrated Improvement in T-Cell Res...Potential of HspE7, SAN DIEGO, May 12 /PRNewswire...on (TSX: NVN) today announced positive immunologic... 1 clinical trial of its lead product,candidate, H...oplasia, or,CIN, a precursor to cervical cancer. H...
Breaking Medicine Technology:GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 2Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 3Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 4Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 5Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 2Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 3Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6Allergy Induced Asthma More Common in Affluent Countries 1377 1Allergy Induced Asthma More Common in Affluent Countries 1377 2Allergy Induced Asthma More Common in Affluent Countries 1377 3IMPACT initiative looks to improve patient participation in clinical trials 1372 1IMPACT initiative looks to improve patient participation in clinical trials 1372 2VirtualScopics Announces 244 35 Million Private Placement 1369 1VirtualScopics Announces 244 35 Million Private Placement 1369 2VirtualScopics Announces 244 35 Million Private Placement 1369 3Pathway Diagnostics Announces Commercial Availability of SensiTrop 28TM 29 HIV Co receptor Tropism Assay 1364 1Pathway Diagnostics Announces Commercial Availability of SensiTrop 28TM 29 HIV Co receptor Tropism Assay 1364 2Pathway Diagnostics Announces Commercial Availability of SensiTrop 28TM 29 HIV Co receptor Tropism Assay 1364 3
..., Ltd. Sponsored Study,Presented at the American P..., May 23, 2007 /PRNewswire/ -- In a six-week study...nia, the Otsuka,Pharmaceutical Co., Ltd. and Brist...piprazole demonstrated significant improvement,com... Positive and,Negative Syndrome Scale (PANSS) Tota...
...ith Monoclonal Antibody,Targeting Interleukin-9 (I...or IL-9 Inhibition in Developing Potential Asthma,...wire-FirstCall/ --,MedImmune, Inc. today announced...ress within the company,s inflammatory,disease pip...,studies with its monoclonal antibody (MAb) target...
Other Medicine Technology:Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 2Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 3Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 4Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 5Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 6Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 7Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 8Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 9MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 2MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 3MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 4MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 5MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 6MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 7